Evidence map›Paper›PMID 41676351›Full record

ArticleDigital discovery2026

A simple compound prioritization method for drug discovery considering multi-target binding.

Alžbeta Kubincová, David L Mobley

Abstract read
In one paragraph

Article in Digital discovery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Alžbeta KubincováDepartment of Pharmaceutical Sciences, University of California Irvine Irvine CA 92697 USA dmobley@uci.edu.ORCID https://orcid.org/0000-0001-6518-681X
David L MobleyDepartment of Pharmaceutical Sciences, University of California Irvine Irvine CA 92697 USA dmobley@uci.edu.ORCID https://orcid.org/0000-0002-1083-5533

Funding

Accelerating drug discovery via ML-guided iterative design and optimizationR35GM148236 · NIGMS · UNIVERSITY OF CALIFORNIA-IRVINE · PI David Lowell Mobley · 2023 to 2026
$2.2M
NIGMS NIH HHS R35 GM148236
6 · The paper itself

Abstract

Active learning is an emerging paradigm used to help accelerating drug discovery, but most prior applications seek solely to optimize potency, whereas multiple properties influence a compound's utility as a drug candidate. We introduce a method for multiobjective ligand optimization, which is able to efficiently handle distinct molecular properties that are expensive to compute, such as binding affinities with respect to multiple protein targets. We validate this protocol retrospectively using docking scores, showing an improved retrieval of the top 0.04-0.4% binders from the dataset with our method compared to greedy acquisition, owing to a better distribution of the compute budget between different properties. Our results also suggest that fitting individual properties separately leads to a better rank correlation of the resulting predictions. This workflow addresses the needs of pharmaceutical research for improving the efficiency of hit-to-lead and lead optimization by considering binding to multiple targets. Our code is freely available on Github: https://github.com/MobleyLab/active-learning-notebooks/blob/main/MultiobjectiveAL.ipynb.

Identifiers

PMID41676351
PMCPMC12888084

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.